Targeting this axis and modulating it with eCBome enzyme/receptor (such as FAAH/TRPV1) blockers may have therapeutic potential in ASD-related anxiety and depressive tendencies as well as behavioral and sociability impairment (Fig. 1). This evidence concerns the gene FAAH and Anxiety.